IRD
Opus Genetics, Inc.
NASDAQ · USHealthcareBiotechnology
$3.05-6.73%
Price as of Jul 20, 2026
IRD profitability
Opus Genetics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 49.6%
- EBITDA margin
- -874.0%
- EBIT margin
- -359.1%
- Net margin
- -892.4%
- Free cash flow margin
- -325.3%
Returns
- Return on equity
- 233.3%
- Return on assets
- -160.1%
- Return on invested capital
- 216.2%
- Asset turnover
- 0.20x
Cash efficiency
- Cash from operations
- -$39.0M
- Cash per share
- $0.74
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.